Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab dose comparison in previously untreated unresectable or metastatic melanoma
2015-004920-67Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nivolumab and ipilimumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of drug-related Grade 3-5 adverse events. Started Feb 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2015-004920-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004920-67.